Fifteen warning letters dispatched by the US Food and Drug Administration in late November illustrate a key challenge companies face in marketing cannabidiol (CBD)-infused cosmetic products.
Amid soaring global interest in all things cannabis and relaxed laws enabling wider use of the plant and increased research into its medicinal benefits, CBD is
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?